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Paliperidone Palmitate 
6-month (PP6M)
Paliperidone Palmitate 6-month (PP6M) 
is an investigational atypical antipsychotic in-
tended for treatment of  schizophrenia in a 
6-month long-acting injectable (LAI) formu-
lation. Schizophrenia is a chronic brain disor-
der affecting approximately 20 million people 
worldwide. It is distinguished by changes in 
emotions, cognition, perceptions and behav-
iour and leads to severe disability. Antipsy-
chotic medication plays a prominent role in 
schizophrenia symptom management. Unfor-
tunately, we are faced with a worldwide prob-
lem of  nonadherence to prescribed medica-
tion, which is frequently the cause of  relapse 
in patients with schizophrenia. LAI antipsy-
chotics enable steady and slow release of  the 
therapeutic agent into the bloodstream, and 
are therefore superior to oral medications in 
terms of  lack of  daily drug administration, 
and at the same time lower relapse rates and 
improved patient outcomes [1,2]. 
Paliperidone palmitate is a LAI formula-
tion of  the atypical antipsychotic paliperidone, 
the primary active metabolite of  risperidone. 
Paliperidone achieves its effect by blockage of  
dopamine 2 receptors, which in turn reduces 
positive symptoms of  psychosis and also has 
stabilizing effect on the affective symptoms. 
Furthermore, by blocking serotonin 2A recep-
tors it enhances dopamine release in certain 
brain regions and in turn reduces motor side 
effects and possibly improves cognitive and 
affective symptoms. Antagonism at the sero-
tonin 7 receptor is mentioned as a possible 
contributor to the antidepressant actions [3].
The Janssen Pharmaceutical Company an-
nounced the submission of  PP6M for the treat-
ment of  adults diagnosed with schizophrenia 
to the U.S. Food and Drug Administration in 
November 2020. The submission is based on 
the Route 6 Study, a randomized, double-blind, 
non-inferiority global Phase 3 study of  702 
adults with schizophrenia from 20 countries, in-
cluding Bulgaria, Czech Republic, France, Hun-
gary, Italy, Poland and Spain. It consisted of  
three phases: a screening phase (up to 28 days), 
a maintenance phase (of  1 or 3 months), and a 
double-blind phase (of  12 months). It was de-
signed to demonstrate that injection of  PP6M 
is not less effective than shorter acting formula-
tion of  paliperidone palmitate 3-month (PP3M) 
for the prevention of  relapse. Participants were 
previously stabilized on corresponding doses 
of  PP1M or PP3M (during maintenance phase). 
Final data revealed non-inferiority of  PP6M 
compared to PP3M on the primary endpoint 
of  time to relapse at the end of  the 12-month 
period in both intent-to-treat and per-protocol 
analysis sets. The safety profile observed for 
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PP6M was congruous with previous research 
of  paliperidone palmitate shorter acting formu-
lations [1,4,5]. 
All in all, if  approved, PP6M will be the 
first and only (LAI) schizophrenia medica-
tion with a twice-yearly dosing regimen. It is 
important to emphasise that PP6M is anoth-
er step towards diminishing nonadherence, 
which is still a challenging aspect of  schizo-
Figure 1. The chemical structure of  Paliperidone Palmitate
phrenia treatment. Needless to say, that kind 
of  a dosing regimen would allow health care 
workers to devote more resources and time to 
psychosocial interventions.
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